- Home
- OGEN
OGEN
Oragenics Inc.
as 11-15-2024 4:00pm EST
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 4.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 738.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $7.74 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | -71.37% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oragenics Inc. News
OGEN Breaking Stock News: Dive into OGEN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
GlobeNewswire
a month ago
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
GlobeNewswire
a month ago
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Benzinga
a month ago
EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate
GlobeNewswire
2 months ago
Oragenics, Inc. Announces Closing of Public Offering
MT Newswires
2 months ago
Top Midday Decliners
MT Newswires
2 months ago
Oragenics Stock Falls After Public Offering Priced to Raise $4.45 Million
GlobeNewswire
2 months ago
Oragenics, Inc. Announces Pricing of Public Offering
Compare OGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGEN Oragenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.